CRISPR技术市场按产品、交付方式、应用和最终用户划分－2025-2032年全球预测

预计到 2032 年，CRISPR 技术市场将成长至 103.2 亿美元，复合年增长率为 14.29%。

本文简要概述了CRISPR技术的科学基础与转化应用轨迹。

CRISPR套件融合了分子生物学、计算设计和转化研究，能够对多种生物的基因组进行精确编辑。酵素工程、嚮导 RNA 优化、递送方式和筛选平台等方面的进步，共同推动了 CRISPR 从一项实验室技术发展成为应用生命科学的核心竞争力。随着基础科学发现的不断成熟，筛检机构和企业正日益致力于将基因编辑应用于治疗、农业改良、诊断和工业生物加工等领域。

本组装发行策略的动态和商业性现实，旨在为研究、产品开发和战略投资提供明智的决策依据。

核酸酶、引导设计和递送系统的技术进步如何重新定义 CRISPR 价值链和应用动态

由于酵素多样化、运算引导设计和先进递送系统等领域的创新融合，CRISPR技术领域正经历显着的变革。新型核酸酶和碱基编辑器正在扩展可实现的编辑范围，而引导RNA化学和演算法设计的进步则提高了特异性并减少了脱靶效应。同时，脂质奈米颗粒製剂、重定向病毒载体和体外细胞修饰等发行策略正在推动更广泛的治疗和农业应用，并重塑价值链。

同时，各组织机构的采纳模式也正在转变。学术团体、生物技术公司、受託研究机构和製药公司正在重新分配资源，将CRISPR技术整合到其药物发现、细胞治疗、诊断检测和菌株工程流程中。随着各组织机构寻求将自身平台优势与临床和商业化专长结合，策略合作和授权协议也变得越来越普遍。法律规范和公众舆论对CRISPR技术的伦理应用也在日益成熟，上市公司正加大对合规性、透明度和相关人员的投入，以加速负责任的部署。

评估近期美国关税措施对CRISPR供应链、采购和生产决策的连锁营运和策略影响

美国近期加征的关税和贸易政策调整为全球CRISPR供应链带来了新的变数，影响了试剂、设备和外包服务的筹资策略。更高的进口关税和相关的合规要求会增加国际采购组件的到岸成本，并增加研究机构和製造商的行政负担。为此，许多相关人员正在重新评估供应商关係，将采购来源多元化到不同地区，并增加库存以应对市场波动。

关税环境也会影响製造和服务活动的战略定位选择。依赖专用酵素、引导RNA合成、套件和试剂的公司可能会加快在地化生产的步伐，或开发替代采购模式，包括与关税优惠地区的契约製造工厂合作。重要的是，其累积影响可能不仅限于价格，还会波及合约条款的修改、关键投入品交货週期的延长以及研发项目时间表的调整。因此，拥有国际业务的机构正在优先考虑供应链前置作业时间、情境规划以及能够减轻关税影响并维持研发连续性的合约条款。

将产品和服务组合、交付方式、应用领域和最终用户画像与营运风险和策略重点连结起来的多维度細項分析

从实际的观点进行细分，可以清楚了解价值和风险在服务产品、交付方式、应用领域和最终用户等方面的具体体现。基于服务产品，市场格局可分为产品和服务两大类：产品途径包括酵素、引导RNA、套件和试剂等核心组件，而服务则包括细胞株工程、gRNA设计和载体建构等实验室能力，以及将平台潜力转化为实验结果的筛检服务。这些服务差异化有助于企业优先考虑对内部能力的投资，而非外包专业知识。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• CRISPR 公司专注于个人化医疗和罕见遗传疾病，并且取得了成长。
• 全球合作研究努力加速商业化
• 整合人工智慧和机器学习技术以优化 CRISPR 基因编辑结果
• CRISPR技术在永续生质燃料和工业生物产品生产的应用
• 递送系统的创新旨在提高 CRISPR 组件的标靶性和效率
• 影响 CRISPR 临床试验核准的监管挑战和伦理考量
• 开发 CRISPR 工具以更有效率地标靶复杂遗传疾病
• 扩大 CRISPR 技术在农业生物技术领域的应用，以改良作物
• 基于CRISPR技术的诊断方法的出现，促进了疾病的快速准确检测。
• 先进编辑技术可提高 CRISPR 治疗应用的精准度

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 CRISPR技术市场：依产品/服务分类

• 产品
  • 酵素
  • 引导RNA
  • 套件和试剂
• 服务
  • 细胞株工程
  • gRNA设计与载体构建
  • 筛检服务

第九章 CRISPR技术市场：依交付方式划分

• 体外
  • 细胞株改造
  • 初代细胞修饰
• In vivo
  • 直接编辑
  • 奈米颗粒递送
  • 重定向向量

第十章 CRISPR技术市场：按应用划分

• 农业用途
  • 畜牧养殖
  • 抗虫害
• 生物医学应用
  • 药物发现与开发
  • 基因治疗
• 诊断
• 工业生物技术
  • 生质燃料生产
  • 微生物菌株工程

第十一章 CRISPR技术市场（按最终用户划分）

• 学术和研究机构
• 生技公司
• 受託研究机构
• 製药公司

第十二章：CRISPR技术市场区域划分

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十三章 CRISPR技术市场（依组别划分）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十四章 各国 CRISPR 技术市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十五章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • AgBiome Inc.
  • Agilent Technologies, Inc.
  • BASF SE
  • Bayer AG
  • Beam Therapeutics Inc.
  • Benson Hill Biosystems, Inc.
  • Caribou Biosciences, Inc.
  • Cibus Inc.
  • CRISPR Therapeutics AG
  • Danaher Corporation
  • Editas Medicine, Inc.
  • GeneCopoeia, Inc.
  • Genscript Biotech Corporation
  • Hera BioLabs
  • Intellia Therapeutics Inc.
  • Lonza Group Ltd.
  • Mammoth Biosciences, Inc.
  • Merck KGaA
  • Pairwise Foods Inc.
  • Qiagen NV
  • Revvity, Inc.
  • Syngenta AG
  • Thermo Fisher Scientific, Inc.
  • ToolGen Inc,
  • Yield10 Bioscience, Inc.

The CRISPR Technology Market is projected to grow by USD 10.32 billion at a CAGR of 14.29% by 2032.

A concise overview of CRISPR's scientific foundations and translational trajectory that frames technological pillars, regulatory context, and commercial relevance

The CRISPR toolkit sits at the intersection of molecular biology, computational design, and translational research, enabling precise edits of genomes across diverse organisms. Advancements in enzyme engineering, guide RNA optimization, delivery modalities, and screening platforms have collectively moved CRISPR from a laboratory technique into a core capability for applied life sciences. As basic science discoveries have matured, institutions and companies are increasingly focused on translating gene editing into therapeutics, agricultural improvements, diagnostics, and industrial bioprocessing.

This introduction frames the report's scope by highlighting the technical pillars-nuclease chemistry, guide design, reagent quality, and delivery strategies-that underpin performance and adoption. It also situates CRISPR within an evolving ecosystem of regulatory scrutiny, ethical debate, and supply chain dynamics. Readers should expect an evidence-based synthesis that balances molecular detail with commercial realities, supporting informed choices across research, product development, and strategic investment.

How converging technological advances in nucleases, guide design, and delivery systems are redefining the CRISPR value chain and adoption dynamics

The landscape of CRISPR technology is undergoing transformative shifts driven by converging innovations in enzyme diversification, computational guide design, and sophisticated delivery systems. New engineered nucleases and base editors have expanded the repertoire of achievable edits, while advances in guide RNA chemistry and algorithmic design are improving specificity and reducing off-target effects. In parallel, delivery strategies such as lipid nanoparticle formulations, retargeted viral vectors, and ex vivo cell modification approaches are enabling broader therapeutic and agricultural applications, thereby reshaping the value chain.

Concurrently, institutional adoption patterns are changing: academic groups, biotech companies, contract research organizations, and pharmaceutical developers are reallocating resources to integrate CRISPR into pipelines for drug discovery, cell therapies, diagnostic assays, and strain engineering. Strategic collaborations and licensing arrangements are increasingly common as organizations seek to combine platform strengths with clinical or commercialization expertise. Regulatory frameworks and public discourse around ethical use are also maturing, prompting companies to invest in compliance, transparency, and stakeholder engagement to accelerate responsible deployment.

Evaluating the cascading operational and strategic effects of recent United States tariff actions on CRISPR supply chains, procurement, and manufacturing decisions

Recent tariff measures and trade policy adjustments implemented by the United States have introduced new variables into global CRISPR supply chains, affecting procurement strategies for reagents, instruments, and outsourced services. Elevated import duties and related compliance requirements can increase landed costs for components sourced internationally and create administrative overhead for research organizations and manufacturers. In response, many stakeholders are reassessing supplier relationships, diversifying procurement to alternate geographies, and increasing inventories to buffer against volatility.

The tariff environment also influences strategic location decisions for manufacturing and service activities. Companies that rely on specialized enzymes, guide RNA synthesis, or kits and reagents may accelerate efforts to localize production or to develop alternative sourcing models, including partnerships with contract manufacturers within tariff-favored jurisdictions. Importantly, the cumulative impact extends beyond pricing: it reshapes contractual terms, lengthens lead times for critical inputs, and can alter timelines for development programs. Consequently, organizations with international operations are prioritizing supply chain transparency, scenario planning, and contract clauses that mitigate tariff exposure while preserving research continuity.

A multidimensional segmentation analysis linking product and service portfolios, delivery approaches, application areas, and end-user profiles to operational risks and strategic priorities

A practical segmentation perspective clarifies where value and risk concentrate across offerings, delivery modalities, applications, and end users. Based on offering, the landscape divides into Product and Services: Product pathways encompass core components such as enzymes, guide RNA, and kits & reagents, while Services include laboratory capabilities like cell line engineering, gRNA design & vector construction, and screening services that convert platform potential into experimental outcomes. These offering distinctions help organizations prioritize investments in in-house capabilities versus outsourced expertise.

Based on delivery method, distinctions between Ex Vivo and In Vivo approaches shape technical and regulatory requirements. Ex Vivo strategies further segment into cell line modification and primary cell modification, each with unique manufacturing, cell handling, and quality control needs. In Vivo delivery subdivides into direct editing, nanoparticle delivery, and retargeting vectors, where biodistribution, immunogenicity, and long-term expression profiles inform development choices. Based on application, CRISPR use cases span agricultural applications, biomedical applications, diagnostics, and industrial biotechnology; agricultural efforts include livestock breeding and pest resistance, biomedical efforts emphasize drug discovery & development and gene therapy, and industrial biotechnology focuses on biofuel production and microbial strain engineering. Based on end-user, demand originates from academic & research institutes, biotech companies, contract research organizations, and pharmaceutical companies, each bringing different procurement cycles, validation expectations, and collaboration models. Collectively, these segmentation lenses reveal where technical complexity, regulatory friction, and commercial opportunity overlap, guiding prioritization of capability building and partnership formation.

How regional regulatory environments, talent pools, and manufacturing hubs across the Americas, Europe Middle East & Africa, and Asia-Pacific shape CRISPR adoption and collaboration strategies

Regional dynamics influence talent access, regulatory pathways, supply chain resilience, and partnership ecosystems. In the Americas, home to large research universities, venture capital concentration, and established clinical trial infrastructures, there is strong momentum for therapeutic development and commercialization. The region's ecosystem tends to favor rapid translation of promising modalities into early-stage clinical work and to support deep collaborations between academic inventors and commercial partners.

Europe, Middle East & Africa present a heterogeneous environment where divergent regulatory regimes and public attitudes shape program design. Several European jurisdictions combine robust scientific capabilities with conservative regulatory evaluation, prompting companies to adopt deliberate engagement strategies and to invest in transparent safety data. Meanwhile, Middle Eastern and African markets show growing interest in agricultural and industrial biotechnology applications, with an emphasis on capacity building. Asia-Pacific exhibits a mix of rapid technical adoption, localized manufacturing strengths, and significant government-backed initiatives to support biotechnology. The region's expansive manufacturing base for reagents and instruments, coupled with advancing clinical capabilities, positions it as a critical node for both supply and collaborative development.

Insights into how reagent developers, service specialists, and strategic partners are structuring capabilities, alliances, and operational excellence to advance CRISPR programs

Key corporate behaviors illuminate how organizations translate technological capability into market traction. Established developers of core reagents and instruments continue to invest in enzyme engineering, reagent quality control, and scalable kit design to meet the demands of both research labs and regulated development programs. Parallel to this, specialized service providers are differentiating through integrated offerings that combine gRNA design, vector construction, and cell line engineering with high-throughput screening, enabling customers to compress discovery timelines.

Strategic alliances and licensing arrangements remain central to scaling complex therapeutic programs, with companies forming cross-sector partnerships to access clinical expertise, manufacturing capacity, or regulatory experience. Contract research organizations and contract manufacturing organizations demonstrate increasing vertical integration, offering end-to-end support from assay development through GMP production. Firms that prioritize robust quality management systems, transparent data packages, and regulatory engagement gain trust from pharmaceutical sponsors and academic collaborators, reinforcing their role in translational pipelines. Taken together, these behaviors underscore that commercial success hinges on technical excellence plus the operational capabilities to support regulated development pathways.

Actionable strategic priorities for industry leaders to build resilient capabilities, diversify supply chains, and accelerate responsible translation of CRISPR innovations

Leaders seeking sustainable advantage should adopt a balanced playbook that combines capability investment with risk mitigation. First, organizations should prioritize modular in-house capabilities for critical-path activities such as enzyme quality control and gRNA validation while outsourcing specialized or scale-dependent functions to trusted service providers. This hybrid approach preserves control over intellectual property and technical standards while enabling agility.

Second, proactively harden supply chains by diversifying suppliers across jurisdictions and by qualifying secondary sources for high-risk inputs. Third, invest in regulatory intelligence and early engagement with authorities to align study designs, safety assessments, and manufacturing controls with evolving expectations. Fourth, cultivate partnerships that pair scientific novelty with clinical or commercial experience, ensuring that platform innovations translate into viable products. Finally, embed data governance, reproducibility practices, and transparent reporting into R&D workflows to build credibility with regulators, funders, and the public. Together, these actions create a resilient foundation for scaling CRISPR-enabled initiatives responsibly and efficiently.

A rigorous mixed-methods research approach combining expert consultations, literature synthesis, and reproducibility-focused data validation to underpin actionable insights

The research methodology integrates primary engagement, expert interviews, and systematic literature synthesis to generate a rigorous, objective analysis. Primary engagement included structured consultations with technical leaders across academia, biotechnology firms, contract research organizations, and pharmaceutical developers to capture real-world operational constraints and evolving requirements. Expert interviews provided qualitative depth on enzyme innovations, delivery challenges, and regulatory trajectories, enabling the study to triangulate practitioner perspectives with documented evidence.

Secondary research encompassed peer-reviewed scientific literature, regulatory guidance documents, patent landscapes, and publicly disclosed corporate materials to map technological progress and institutional behavior. Data synthesis emphasized reproducibility, cross-validation of claims, and contextual interpretation of technical performance metrics. Throughout the process, methodological safeguards were applied to minimize bias, including diverse expert sampling and transparent citation of sources used to inform technical assessments. The resulting methodology supports conclusions that are actionable for scientific, operational, and strategic audiences.

A synthesis of CRISPR's maturation across scientific, operational, and regulatory dimensions that identifies enduring challenges and near-term enablers of translation

CRISPR technology has progressed from a transformative scientific discovery to a foundational platform with tangible translational pathways across therapeutics, agriculture, diagnostics, and industrial biotechnology. Progress in enzyme engineering, guide design, delivery modalities, and integrated services has reduced technical barriers, yet persistent challenges remain in delivery specificity, regulatory alignment, and supply chain resilience. As adoption broadens, the interplay of technical, regulatory, and commercial considerations will determine which applications reach clinical and market maturity first.

Looking forward, stakeholders that invest in robust quality systems, diversify procurement strategies, and engage early with regulatory authorities will be best positioned to convert platform capability into sustainable products. Moreover, strategic partnerships that combine deep technical expertise with clinical development capacity will accelerate translation while distributing risk. In sum, CRISPR stands as a high-impact platform whose realized value will depend on coordinated advances in science, operations, and governance.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Growth of CRISPR companies focusing on personalized medicine and rare genetic diseases
• 5.2. Collaborative global research efforts accelerating CRISPR technology commercialization
• 5.3. Integration of AI and machine learning to optimize CRISPR gene-editing outcomes
• 5.4. CRISPR applications in creating sustainable biofuels and industrial bioproducts
• 5.5. Innovations in delivery systems improving CRISPR component targeting and efficiency
• 5.6. Regulatory challenges and ethical considerations shaping CRISPR clinical trial approvals
• 5.7. Development of CRISPR tools targeting complex genetic disorders with increased efficacy
• 5.8. Expansion of CRISPR technology in agricultural biotechnology for crop improvement
• 5.9. Emergence of CRISPR-based diagnostics driving rapid and accurate disease detection
• 5.10. Advancements in prime editing techniques enhancing CRISPR precision for therapeutic applications

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CRISPR Technology Market, by Offering

• 8.1. Product
  • 8.1.1. Enzymes
  • 8.1.2. Guide RNA
  • 8.1.3. Kits & Reagents
• 8.2. Services
  • 8.2.1. Cell Line Engineering
  • 8.2.2. gRNA Design & Vector Construction
  • 8.2.3. Screening Services

9. CRISPR Technology Market, by Delivery Method

• 9.1. Ex Vivo
  • 9.1.1. Cell Line Modification
  • 9.1.2. Primary Cell Modification
• 9.2. In Vivo
  • 9.2.1. Direct Editing
  • 9.2.2. Nanoparticle Delivery
  • 9.2.3. Retargeting Vectors

10. CRISPR Technology Market, by Application

• 10.1. Agricultural Applications
  • 10.1.1. Livestock Breeding
  • 10.1.2. Pest Resistance
• 10.2. Biomedical Applications
  • 10.2.1. Drug Discovery & Development
  • 10.2.2. Gene Therapy
• 10.3. Diagnostics
• 10.4. Industrial Biotechnology
  • 10.4.1. Biofuel Production
  • 10.4.2. Microbial Strain Engineering

11. CRISPR Technology Market, by End-User

• 11.1. Academic & Research Institutes
• 11.2. Biotech Companies
• 11.3. Contract Research Organizations
• 11.4. Pharmaceutical Companies

12. CRISPR Technology Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. CRISPR Technology Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. CRISPR Technology Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2024
• 15.2. FPNV Positioning Matrix, 2024
• 15.3. Competitive Analysis
  • 15.3.1. AgBiome Inc.
  • 15.3.2. Agilent Technologies, Inc.
  • 15.3.3. BASF SE
  • 15.3.4. Bayer AG
  • 15.3.5. Beam Therapeutics Inc.
  • 15.3.6. Benson Hill Biosystems, Inc.
  • 15.3.7. Caribou Biosciences, Inc.
  • 15.3.8. Cibus Inc.
  • 15.3.9. CRISPR Therapeutics AG
  • 15.3.10. Danaher Corporation
  • 15.3.11. Editas Medicine, Inc.
  • 15.3.12. GeneCopoeia, Inc.
  • 15.3.13. Genscript Biotech Corporation
  • 15.3.14. Hera BioLabs
  • 15.3.15. Intellia Therapeutics Inc.
  • 15.3.16. Lonza Group Ltd.
  • 15.3.17. Mammoth Biosciences, Inc.
  • 15.3.18. Merck KGaA
  • 15.3.19. Pairwise Foods Inc.
  • 15.3.20. Qiagen NV
  • 15.3.21. Revvity, Inc.
  • 15.3.22. Syngenta AG
  • 15.3.23. Thermo Fisher Scientific, Inc.
  • 15.3.24. ToolGen Inc,
  • 15.3.25. Yield10 Bioscience, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 11. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. MIDDLE EAST CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASEAN CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GCC CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. EUROPEAN UNION CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. BRICS CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. G7 CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. NATO CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. CRISPR TECHNOLOGY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 28. CRISPR TECHNOLOGY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CRISPR TECHNOLOGY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ENZYMES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GUIDE RNA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY KITS & REAGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GRNA DESIGN & VECTOR CONSTRUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY SCREENING SERVICES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY REGION, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CELL LINE MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PRIMARY CELL MODIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY REGION, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIRECT EDITING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY NANOPARTICLE DELIVERY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY RETARGETING VECTORS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY LIVESTOCK BREEDING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PEST RESISTANCE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 155. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 157. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 159. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 161. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 163. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 165. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 167. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOFUEL PRODUCTION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 169. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 171. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 173. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY MICROBIAL STRAIN ENGINEERING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 177. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 179. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 181. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 182. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 183. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 184. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 185. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 186. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 187. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 188. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY BIOTECH COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 189. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 190. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 191. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 192. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 193. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 194. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 195. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 196. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 197. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 198. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 199. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 200. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 201. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 202. GLOBAL CRISPR TECHNOLOGY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 203. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 205. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 207. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 209. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 211. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 213. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 215. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 217. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 219. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 220. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 221. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 222. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 223. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 224. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 225. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 226. AMERICAS CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 227. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 230. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 231. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 232. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 233. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 234. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 235. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 236. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 237. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 238. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 239. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 240. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 241. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 242. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 243. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 244. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 245. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 246. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 247. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 248. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 249. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 250. NORTH AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 251. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 252. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 253. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 254. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 255. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 256. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 257. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 258. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 259. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 260. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 261. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 262. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 263. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 264. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 265. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 266. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 267. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 268. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 269. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 270. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 271. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 272. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 273. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 274. LATIN AMERICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 275. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 276. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 277. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 278. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 279. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 280. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 281. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 282. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 283. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 284. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 285. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 286. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 287. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 288. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 289. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 290. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 291. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 292. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 293. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 294. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 295. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 296. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 297. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 298. EUROPE, MIDDLE EAST & AFRICA CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2025-2032 (USD MILLION)
• TABLE 299. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 300. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 301. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2018-2024 (USD MILLION)
• TABLE 302. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY OFFERING, 2025-2032 (USD MILLION)
• TABLE 303. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 304. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY PRODUCT, 2025-2032 (USD MILLION)
• TABLE 305. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2018-2024 (USD MILLION)
• TABLE 306. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY SERVICES, 2025-2032 (USD MILLION)
• TABLE 307. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2018-2024 (USD MILLION)
• TABLE 308. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY DELIVERY METHOD, 2025-2032 (USD MILLION)
• TABLE 309. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2018-2024 (USD MILLION)
• TABLE 310. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY EX VIVO, 2025-2032 (USD MILLION)
• TABLE 311. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2018-2024 (USD MILLION)
• TABLE 312. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY IN VIVO, 2025-2032 (USD MILLION)
• TABLE 313. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 314. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
• TABLE 315. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 316. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY AGRICULTURAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 317. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2018-2024 (USD MILLION)
• TABLE 318. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY BIOMEDICAL APPLICATIONS, 2025-2032 (USD MILLION)
• TABLE 319. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 320. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY INDUSTRIAL BIOTECHNOLOGY, 2025-2032 (USD MILLION)
• TABLE 321. EUROPE CRISPR TECHNOLOGY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
• TABLE 322. EUROPE CRISPR TECHNOLOGY MA